Action RNAZ TRANSCODE THERAPEUTICS, INC.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Autres langues TransCode Therapeutics, Inc.

Actions

RNAZ

US89357L3033

Marché Fermé - Nasdaq
Autres places de cotation
 22:30:01 03/05/2024 		Varia. 5j. Varia. 1 janv.
0,82 USD +15,98% Graphique intraday de TransCode Therapeutics, Inc. +49,12% -87,56%
15/04 TransCode Therapeutics, Inc. annonce l'autorisation de la FDA pour le lancement d'un essai clinique de phase 1/2 avecttx-Mc138 chez des patients atteints de tumeurs solides avancées CI
01/04 TransCode Therapeutics, Inc. annonce ses résultats pour l'exercice clos le 31 décembre 2023 CI

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
TransCode Therapeutics : Shareholder Meeting - Form 8-K
Certain Warrants of TransCode Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 22-APR-2024.
Certain Stock Options of TransCode Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 22-APR-2024.
Certain Common Stock of TransCode Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 22-APR-2024.
TransCode Therapeutics Cleared by FDA for Phase 1/2 Trial of TTX-MC138 for Advanced Solid Tumors
TransCode Therapeutics Announces FDA Clearance To Initiate Phase 1/2 Clinical Trial with TTX-MC138 in Patients with Advanced Solid Tumors
TransCode Therapeutics, Inc. Announces Fda Clearance to Initiate Phase 1/2 Clinical Trial Withttx-Mc138 in Patients with Advanced Solid Tumors
TransCode Therapeutics Reports 2023 Results; Provides Business Update
TransCode Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
TransCode Therapeutics Announces Appointment of Daniel Vlock, M.D., as Chief Medical Officer
TransCode Therapeutics, Inc. Announces Appointment of Daniel Vlock, M.D., as Chief Medical Officer
TransCode Therapeutics and Akribion Genomics Report Progress Developing CRISPR-Derived Technology for Cancer Treatment
TransCode Therapeutics, Inc. and Akribion Genomics Report Progress Developing CRISPR-Derived Technology for Cancer Treatment
TransCode Therapeutics Reports Publication of United States Patent Application Covering TransCode’s RIG-I Agonist Immunotherapeutic
TransCode Therapeutics Reports Publication of United States Patent Application Covering TransCode?s RIG-I Agonist Immunotherapeutic
Nasdaq Determines TransCode Therapeutics Compliance with Minimum Stockholders’ Equity Requirement and Continued Listing on The Nasdaq Stock Market
TransCode Therapeutics, Debiopharm Collaborate to Develop Nucleic Acid Therapies for Cancer
TransCode Therapeutics and Debiopharm Announce Collaboration to Develop Targeted Nucleic Acid Therapeutics for Cancer
TransCode Therapeutics and Debiopharm Announce Collaboration to Develop Targeted Nucleic Acid Therapeutics for Cancer
TransCode Therapeutics Announces Closing of $7.25 Million Public Offering
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action RNAZ
  4. Actualités TransCode Therapeutics, Inc.
  5. Autres langues